Toronto – November 10, 2026 -- Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) will put three senior executives in front of investors at the Stifel 2026 Healthcare Conference in New York City, with President Richard Fabian presenting on Thursday, November 12, 2026, at 8:40 a.m. Eastern Time.
Profound will broadcast Fabian's November 12 session live and archive it online
The commercial-stage interventional MRI (iMRI) company will make the webcast available on its website. Chief Executive Officer and Chairman Arun Menawat and Chief Financial Officer Matthew Sobczyk will join Fabian for one-on-one investor meetings during the conference.
Investors seeking a one-on-one slot must go through their Stifel representative.
TULSA-PRO holds FDA clearance and approvals in Europe, Canada, Saudi Arabia, India, Australia/New Zealand and the UAE
TULSA-PRO, the company's flagship platform, enables MRI-guided, incision-free prostate ablation. The FDA has cleared it in the United States for transurethral ultrasound ablation (TULSA) of prostate tissue. Profound says the approach is designed to minimize side effects typically associated with surgery or radiation, such as urinary incontinence and erectile dysfunction.
Sonalleve carries an FDA Humanitarian Device Exemption for osteoid osteoma treatment in the extremities
Profound's second product, the MRI-guided Sonalleve therapy, is also cleared or approved in Europe, Canada, China and Saudi Arabia. Its indications include pain palliation of bone metastases, desmoid tumors, uterine fibroids and adenomyosis. The company is exploring further applications, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.